BIRC5 and hepatocellular carcinoma: In vitro studies have suggested that BIRC5/Survivin could be implicated in chemotherapy resistance of Irinotecan in colon adenocarcinoma (COAD), Oxaliplatin in esophageal squamous and esophageal adenocarcinoma (ESCA) and Cisplatin in hepatocellular carcinoma (LIHC) [66–68].